• 1
    Katchinski M, Wank U, Ducree M, Schirra J, Arnold R. Cisapride stimulates human esophageal motility. Digestion 1995; 56: 1538.
  • 2
    Ceccatelli P, Janssens J, Vantrappen G, Cucchiara S. Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 1988; 29: 6315.
  • 3
    Gilbert R, Dodds WJ, Kahrilas P, Hogan WJ, Lipman S. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 13316.
  • 4
    Castell DO, Sigmund C, Patterson D, et al. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. Am J Gastroenterol 1998; 93: 54752.
    Direct Link:
  • 5
    Anonymous. Cisapride for nocturnal heartburn. Med Lett Drugs Ther 1994; 36: 113.
  • 6
    McCallum R. Cisapride: a new class of prokinetic agent. The ACG Committee on FDA-related matters. American College of Gastroenterology. Am J Gastroenterol 1991; 86: 13549.
  • 7
    Goldin G, Marcinkiewicz M, Zbroch T, Bityutskiy L, McCallum R, Sarosiek J. Esophagoprotective potential of cisapride: an additional benefit for gastroesophageal reflux disease. Dis Dis Sci 1997; 42: 13629.
  • 8
    Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000; 95: 145662.
    Direct Link:
  • 9
    Mittal RK, McCallum R. Characteristics of transient lower esophageal sphincter relaxation in humans. Am J Physiol 1987; 252(Gastrointest Liver Physiol 1987; 15): G63641.
  • 10
    Mittal RK, Holloway R, Penagini R, Backshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109: 60110.
  • 11
    Holloway R, Penagini R, Ireland A. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995; 268(Gastrointest Liver Physiol 1995; 31): G12833.
  • 12
    Rechtschaffen A, Kales A, eds. A Manual of Standardized Terminology: Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles, CA: UCLA Brain Information Service, 1968.
  • 13
    Gilleminault C. EEG arousals: scoring rules and examples. Sleep 1992; 15: 17384.
  • 14
    Dodds WJ, Hogan WJ, Helm JF, Dent J. Pathogenesis of reflux esophagitis. Gastroenterology 1981; 81: 37694.
  • 15
    Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal esophagus. Am J Gastroenterol 1974; 62: 32532.
  • 16
    Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980; 65: 25667.
  • 17
    Orr W, Allen M, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 1994; 89: 50912.
  • 18
    Freidin N, Fisher MJ, Taylor W, et al. Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. Gut 1991; 32: 12759.
  • 19
    McCallum R, Berkowitz D, Lerner E. Gastric emptying in patients with gastroesophageal reflux. Gastroenterology 1981; 80: 28591.
  • 20
    Galmiche J-P, Janssen J. The pathophysiology of gastro-oesophageal reflux disease: an overview. Scand J Gastroenterol 1995; 30(Suppl. 211): 718.
  • 21
    Boeckxstaens G, Hirsch D, Fakhry N, Holloway R, D'Amato M, Tytgat GN. Involvement of cholecystokinin A receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol 1998; 93(10): 18238.
    Direct Link:
  • 22
    Holloway R, Hongo M, Berger K, McCallum R. Gastric distension: a mechanism for postprandial gastroesophageal reflux. Gastroenterology 1985; 89: 77984.
  • 23
    Holloway R, Kocyan P, Dent J. Provocation of transient lower esophageal sphincter relaxations by meals in patients with symptomatic gastroesophageal reflux. Dig Dis Sci 1991; 36: 10349.
  • 24
    Wysowski D, Bacsanyi J. Cisapride and fatal arrhythmia. (Letter). N Engl J Med 1996; 335: 2901.
  • 25
    Kahrilas P, Quigley E, Castell D, Spechler S. The effect of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 15039.